Overview

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the pharmacokinetics and pharmacodynamics of hydromorphone oral solution in pediatric subjects aged 28 days to 16 years inclusive. The secondary objectives are to characterize the safety and efficacy of hydromorphone oral solution in pediatric subjects aged 28 days to 16 years inclusive.
Phase:
Phase 4
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Hydromorphone
Pharmaceutical Solutions